Ilaprazole, a proton pump inhibitor, has been approved and marketed in Koreaand China for the treatment of gastric ulcer, duodenal ulcer,gastroesophageal reflux disease, and erosive esophagitis. Here, ATP12A is linked to duodenal ulcer.